QPS Respiratory Brochure
4
Respiratory clinical trials the world over, have one name - QPS Smoking High Costs Asthma COPD
-
Upload
qps-holdings-llc -
Category
Health & Medicine
-
view
303 -
download
1
description
QPS has a long tradition in conducting trials for respiratory diseases such as asthma and COPD in all clinical trial phases. It’s exhaustive quantum of work as a leading CRO for respiratory drug development has contributed to its expertise in effectively conducting clinical trials in this domain. QPS benefits from extensive experience, having conducted over 100 Phase I - IV pulmonary and respiratory studies. This experience covers a range of indications including, but not limited to COPD, Asthma, Interstitial Lung Disease (ILD) and Smoking Cessation. Our well-trained staff work together to produce high-quality studies. QPS has a strong history of supporting clinical research for new pulmonary and respiratory medications in Asia, Europe and the United States. We have the experience to take your compound from the initial planning process, to the collection of clinical evidence, to registration. Our experience can reduce your time-to-market and minimize your costs. QPS will plan your clinical study from start to finish, putting the right team and protocol in place to ensure your trial runs smoothly.
Transcript of QPS Respiratory Brochure
Respiratory clinical trialsthe world over, have one name - QPS
Smoking High Costs
Asthma
COPD
THE GLOBAL FOOTPRINT OF COPD AND ASTHMA
CURRENT CHALLENGESChanging environmental conditions along with increases in
smoking, air pollution and urbanization has lead to an
increase in the prevalence of respiratory diseases. Clinical
research plays an important role in understanding risk
factors, drawbacks of current therapy and to find novel
therapies for respiratory diseases. However, the cost and
time for conducting clinical trials for respiratory diseases is
higher than other diseases due to costly and time consuming
testing methods. Patients are required to be tested for a
longer duration leading to an increase in the total time
required for drug effectiveness than seen in other diseases.
The global burden of respiratory diseases like bronchial asthma
appears to be increasing worldwide, affecting in particular subjects
living in urban areas. Evidence suggests that urbanization, with its
high levels of vehicle emissions and a westernised lifestyle are
linked to the rising frequency of these diseases observed in most
industrialized countries.
300 million people of all ages worldwide have asthma.
Globally, 250 000 people die of asthma every year.
Chronic obstructive pulmonary disease (COPD) affects
210 million people.
Chronic obstructive pulmonary disease was the fifth cause of
death in 2002 and it is projected to be the fourth cause of
mortality by 2030.
QPS has a long tradition in conducting trials for
respiratory diseases such as asthma and COPD in
all clinical trial phases. It’s exhaustive quantum of work
as a leading CRO for respiratory drug development has
contributed to its expertise in effectively conducting clinical trials
in this domain.
QPS benefits from extensive experience, having conducted over
100 Phase I - IV pulmonary and respiratory studies. This
experience covers a range of indications including, but not limited
to COPD, Asthma, Interstitial Lung Disease (ILD) and Smoking
Cessation. Our well-trained staff work together to produce
high-quality studies. QPS has a strong history of supporting
clinical research for new pulmonary and respiratory medications
in Asia, Europe and the United States. We have the experience to
take your compound from the initial planning process, to the
STUDY PARTICIPANTS
Finding the right study patients is crucial for the success
of your pulmonary and respiratory trials. QPS has a
worldwide database of clinical investigators to ensure
high patient enrollment rates conforming to strict
selection criteria. The incidence of respiratory disease is
so widespread that we can recruit patients with
pulmonary or respiratory conditions in a number of
different countries.
EXPERIENCED INVESTIGATORS
QPS has developed close relationships with the
investigators who conduct your clinical trials. These
relationships are the foundation for ensuring quality
studies are performed. We take pride in our ability to
leverage the skills of the world’s most experienced
investigators for every clinical trial we conduct.
QPS FOR YOUR NEXT PULMONARY OR RESPIRATORY TRIAL
Whether you need clinical trials of small molecules,
biologics, immunotherapies or other medications, QPS
has the experience and resources to handle your trials
and get your product to market.
Should you want to discuss your questions in more
detail with one of our experts, please contact us directly
WHYCHOOSE
QPS?Knowledge and
Experience = Expertise
collection of clinical evidence, to registration. Our
experience can reduce your time-to-market and
minimize your costs. QPS will plan your clinical study
from start to finish, putting the right team and protocol in
place to ensure your trial runs smoothly.
REFERENCES:
1. D'Amato G. Environmental urban factors (air pollution and allergens) and the rising trends in allergic respiratory diseases. Allergy. August 2002;57(S72):30-33.
2. http://www.who.int/gard/publications/chronic_respiratory_diseases.pdf
3. http://www.european-lung-foundation.org/63-european-lungfoundation-elf-burden-in-europe.htm
4. http://www.japi.org/february_2012_special_issue_copd/01_editorial_india_needs_a.pdf
5. Kuo, L, Yang, P, Kuo, S Trends in the Mortality of Chronic Obstructive Pulmonary Disease in Taiwan 1981–2002. J Formos. Med Assoc 2005;104,89-93
6. http://www.ginasthma.org/pdf/GINABurdenReport.pdf
7. http://www.researchandmarkets.com/reports/1958232/clinical_trial_recruitment_in_respiratory
Corporate OfficeDelaware Technology Park, 3 Innovation Way, Suite 240, Newark, DE 19711
Email: [email protected] TEL: + 1 302 369 5601 FAX: + 1 302 369 5602
2012 QPS Holdings. All Rights Reserved
www.qps.com
